Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q3 2021 call → NOWe need to determine if management conveys that the business is currently outgrowing the company's size, with disproportionate scale relative to its smallness. Look for statements about current demand, commitments, or activity being large relative to the company's current size. From transcript: Tom Caulfield says "we are really at the beginning of this journey. We expect this will become more apparent in 2022 and beyond as our revenue will continue to grow with the capacity investments we are making." That suggests future growth, not necessarily current disproportion. Dave Reeder mentions "we are capacity limited, and we are working diligently every day to get new tooling in and get factories ramped and online so that we can produce more wafers for our customers." That indicates demand exceeds capacity, but does that convey disproportion? They are capacity limited, meaning they can't meet demand, but that's common. They also mention "we have significant business visibility and certainty with customer long-term agreements." They talk about LTAs covering $20 billion+ revenue, which is large relative to current revenue (~$1.7B per quarter, so annual ~$6.8B). $20B over three years is about $6.7B per year, which is roughly current revenue. So not necessarily disproportionate. But they also say "we are still dealing with shortages of what we can supply to our key customers in 2022 and figuring out how we could produce more" - that indicates demand exceeds supply, but not necessarily that the company is small relative to the opportunity. Look for explicit statements about the company being small relative to what's happening. Tom says "we are really at the beginning of this journey" and "we expect this will become more apparent in 2022 and beyond" - that suggests future growth, not current disproportion. Also, they mention "we have significant business visibility and certainty with customer long-term agreements. This gives us confidence that the fundamentals of our business will continue to improve at a rapid pace over the next three to five years." That's about future.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.